Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

ABSTRACT: This SuperSeries is composed of the SubSeries listed below.

ORGANISM(S): Mus musculus

PROVIDER: GSE181152 | GEO | 2021/12/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

Project description:This study reveals supeior efficiacy of triple combination treatment (TCT) based on anti-PD-(L)1 and anti-4-1BB/OX40 and describes immunological mechanisms underlying synergism between the treatment components

2021-12-21 | GSE185566 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

2021-12-21 | GSE181150 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

2021-12-21 | GSE181142 | GEO

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties

| PRJNA750792 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties II

| PRJNA750798 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties I

| PRJNA750781 | ENA

Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

Project description:Combinatorial Immunotherapy Induces Tumor Infiltrating CD8+ T Cells with Distinct Functional, Migratory, and Stem-Like Properties III

| PRJNA769684 | ENA

Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1-CD8+ Tumor-Infiltrating T Cells.

Project description:An improved understanding of the anti-tumor CD8+ T cell response after checkpoint blockade would enable more informed and effective therapeutic strategies. Here we examined the dynamics of the effector response of CD8+ tumor-infiltrating lymphocytes (TILs) after checkpoint blockade therapy. Bulk and single-cell RNA profiles of CD8+ TILs after combined Tim-3+PD-1 blockade in preclinical models revealed significant changes in the transcriptional profile of PD-1- TILs. These cells could be divided into subsets bearing characterstics of naive-, effector-, and memory-precursor-like cells. Effector- and memory-precursor-like TILs contained tumor-antigen-specific cells, exhibited proliferative and effector capacity, and expanded in response to different checkpoint blockade therapies across different tumor models. The memory-precursor-like subset shared features with CD8+ T cells associated with response to checkpoint blockade in patients and was compromised in the absence of Tcf7. Expression of Tcf7/Tcf1 was requisite for the efficacy of diverse immunotherapies, highlighting the importance of this transcriptional regulator in the development of effective CD8+ T cell responses upon immunotherapy.

| S-EPMC6336113 | biostudies-literature

JAML immunotherapy targets recently activated tumor-infiltrating CD8<sup>+</sup> T cells.

Project description:Junctional adhesion molecule-like protein (JAML) serves as a co-stimulatory molecule in γδ T cells. While it has recently been described as a cancer immunotherapy target in mice, its potential to cause toxicity, specific mode of action with regard to its cellular targets, and whether it can be targeted in humans remain unknown. Here, we show that JAML is induced by T cell receptor engagement, reveal that this induction is linked to cis-regulatory interactions between the CD3D and JAML gene loci. When compared with other immunotherapy targets plagued by low target specificity and end-organ toxicity, we find JAML to be mostly restricted to and highly expressed by tissue-resident memory CD8+ T cells in multiple cancer types. By delineating the key cellular targets and functional consequences of agonistic anti-JAML therapy in a murine melanoma model, we show its specific mode of action and the reason for its synergistic effects with anti-PD-1.

| S-EPMC10366340 | biostudies-literature

Checkpoint blockade immunotherapy induces dynamic changes in PD-1-CD8+ tumor-infiltrating T cells

Project description:An improved understanding of the anti-tumor CD8+ T cell response after checkpoint blockade would enable more informed and effective therapeutic strategies. Here we examined the dynamics of the effector response of CD8+ tumor-infiltrating lymphocytes (TILs) after checkpoint blockade therapy. Bulk and single-cell RNA profiles of CD8+ TILs after combined Tim-3+PD-1 blockade in preclinical models revealed significant changes in the transcriptional profile of PD-1? TILs. These cells could be divided into subsets bearing characterstics of naive-, effector-, and memory-precursor-like cells. Effector- and memory-precursor-like TILs contained tumor-antigen-specific cells, exhibited proliferative and effector capacity, and expanded in response to different checkpoint blockade therapies across different tumor models. The memory-precursor-like subset shared features with CD8+ T cells associated with response to checkpoint blockade in patients and was compromised in the absence of Tcf7. Expression of Tcf7 was requisite for the efficacy of diverse immunotherapies, highlighting the importance of this transcriptional regulator in the development of effective CD8+ T cell responses upon immunotherapy.

2019-01-16 | GSE122969 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data